Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Free Radic Biol Med. 2021 Dec 3;178:125–133. doi: 10.1016/j.freeradbiomed.2021.11.031

Figure 4. MPO-expressing cells are detected in primary motor cortex of ALS patients and co-localized with CEP deposition.

Figure 4.

A. Bar graph showing expression of MPO gene in different human brain cells in published brain single cell RNA sequencing database (https://www.brainrnaseq.org). B. Representative confocal images of brain tissues from non-ALS patients, SOD1-type ALS patients, and C9orf72-type ALS patients immunostained for MPO. Scale bar is 28 μm C. Quantification of fractions of MPO+ cells showing significantly more MPO+ cells in SOD1-type ALS patients’ primary motor cortex. D. Representative confocal images showing brain tissues from non-ALS patients, SOD1-type ALS patients, and C9orf72-type ALS patients immunostained for MPO and CEP. Scale bar is 14 μm. E. Quantification of fractions of MPO+CEP+ cells revealing significantly more MPO+CEP+ cells in SOD1-type ALS patients’ primary motor cortex. All data are mean ± s.e.m. Comparisons between groups were made using one-way ANOVA followed by Tukey’s post hoc test. * p < 0.05, ** p < 0.01, and *** p < 0.001. MPO, myeloperoxidase. ns, not significant.